Login to Your Account



The Medicines Co. Takes Heart

Cangrelor Steps Up to 'Platelet,' Hits Phase III Data Home Run

By Randy Osborne
Staff Writer

Monday, March 11, 2013
in_the_clinic.jpg

Bolstering its news in January, when the firm disclosed that the intravenous antiplatelet cangrelor had proven strong in a Phase III trial as compared to oral clopidogrel, The Medicine Co.'s scientific team offered specifics over the weekend at the American College of Cardiology Scientific Session in San Francisco.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription